Treatment of myelodysplastic syndromes (MDS)
Mode of action of hypomethylating agents for MDS
Panobinostat and donor lymphocyte infusions in patients with high-risk AML and MDS
Generics for chronic myeloid leukemia treatment – a hot topic at ASH 2016 as imatinib patent expires
How can the study of familial leukemias help us to understand sporadic leukemias?
Jane E. Churpek